Resources Repository
-
ReviewPublication 2013Public Health Economics: Review of Guidance for Economic Evaluation
This is a systematic review of published guidance for the economic evaluation of public health …
This is a systematic review of published guidance for the economic evaluation of public health interventions. Public Health Economics is the science and art of supporting decision making as to how society can use its available resources to advance health, and minimize opportunity cost. In this review, the authors identified 5 international guidance documents, 7 UK guidance documents and 4 documents by individual commentators. The papers reviewed identify the main methodological challenges that face analysts…
Cost-Effectiveness Analysis | Health/Medicine | Priority Setting/Ethics | Costing Methods | Health Systems | Policy/Regulation | Economics/Finance | Science/Technology | Europe -
ArticlePublication 2013Public Finance of Rotavirus Vaccination in India and Ethiopia: Extended CEA
This study uses extended cost-effectiveness analysis (ECEA) to evaluate a hypothetical publicly financed program for …
This study uses extended cost-effectiveness analysis (ECEA) to evaluate a hypothetical publicly financed program for rotavirus vaccination in India and Ethiopia. The authors measured program impact on: (1) averted rotavirus deaths; (2) reduction in household expenditures; (3) financial risk protection; and (4) distributional consequences across the country’s wealth strata. In India and Ethiopia, the program was predicted to decrease rotavirus deaths substantially, and effectively provide financial risk protection among the poor, while also reducing household…
Cost-Effectiveness Analysis | Health/Medicine | Priority Setting/Ethics | Health Outcomes | Infectious Diseases | Child/Nutrition | Social Determinants | Culture/Society | Economics/Finance | Sub-Saharan Africa | Asia & Pacific -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Cost-Effectiveness Analysis | Health/Medicine | Costing Methods | Health Outcomes | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ReviewPublication 2012Modeling Preventative Strategies Against HPV-Related Disease in Developed Countries
This review article is part of a special supplement on “Comprehensive Control of HPV Infections …
This review article is part of a special supplement on “Comprehensive Control of HPV Infections and Related Diseases.” At the time of its writing, prophylactic vaccination against human papillomavirus (HPV) in pre-adolescent females had been introduced in most developed countries, supported by modeled evaluations that had almost universally found vaccination of pre-adolescent females to be cost-effective. Vaccination of pre-adolescent males had been shown to be cost-effective at a cost per vaccinated individual of ~US$400-500 if…
Cost-Effectiveness Analysis | Health/Medicine | Mathematical Models | Chronic Disease/Risk | Social Determinants | Health Systems | Global -
GuidelinesPublication 2012State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Task Force-3
State-transition modeling includes both Markov model cohort simulation as well as individual-based (first-order Monte Carlo) …
State-transition modeling includes both Markov model cohort simulation as well as individual-based (first-order Monte Carlo) microsimulation. These models have been used in many different populations and diseases, and their applications range from personalized health care strategies to public health programs. Most frequently, state-transition models are used in the evaluation of risk factor interventions, screening, diagnostic procedures, treatment strategies, and disease management programs. Recommendations are made on choice of model type (cohort vs. individual-level model), model…
State-Transition | Health/Medicine | Mathematical Models | Microsimulation -
GuidelinesPublication 2012Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Task Force-1
This paper provides an overview of the work of the joint Task Force between the …
This paper provides an overview of the work of the joint Task Force between the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Society for Medical Decision Making (SMDM), provides the overarching recommendations, and discusses future work that is needed. The audience for these papers includes anyone who build models, stakeholders who utilize their results, and those concerned with the use of models to support decision making. This article is part 1 of…
State-Transition | Health/Medicine | Costing Methods | Health Outcomes | Value of Information | Mathematical Models | Dynamic Transmission | Microsimulation | Calibration/Validation | Dynamic Simulation | Decision Analysis | Infectious Diseases -
ArticlePublication 2012Value of Family Planning for Improving Maternal Health in Rural Afghanistan
This article, published in the Afghanistan Journal of Public Health, uses a model designed to …
This article, published in the Afghanistan Journal of Public Health, uses a model designed to simulate the natural history of pregnancy and associated maternal mortality and morbidity contextualized to Afghanistan to assess the cost-effectiveness of family planning in the rural Maywand district of Kandahar. Using total fertility rate, pregnancy-related complications, maternal mortality ratio, lifetime risk of maternal death, and proportionate mortality ratio as outcomes, the model finds that increasing family planning from 8% to 30-50% could…
Cost-Effectiveness Analysis | Health/Medicine | Health Outcomes | Maternal/Reproductive Health | Policy/Regulation | Asia & Pacific -
BookPublication 2012Elgar Companion to Health Economics, 2nd Edition
This collection brings together more than 50 contributions from some of the most influential researchers in …
This collection brings together more than 50 contributions from some of the most influential researchers in health economics. It covers theoretical and empirical issues in health economics, with a range of material on equity and efficiency in health care systems, health technology assessment and issues of concern for developing countries. This revised second edition is expanded to include four new chapters, while all existing chapters have been extensively updated. The Elgar Companion to Health Economics, Second Edition…
Cost-Effectiveness Analysis | Health/Medicine | Decision Theory | Probability/Bayes | Preferences/Values | Priority Setting/Ethics | Costing Methods | Value of Information | Health Systems | Policy/Regulation | Economics/Finance | Global -
ArticlePublication 2011Health and Economic Impact of HPV 16/18 Vaccination and Cervical Cancer Screening in Eastern Africa
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe …
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to develop models of HPV-related infection and disease. For each country, they assessed HPV vaccination of girls before age 12 followed by screening with HPV DNA testing once, twice, or three times per lifetime (at ages 35, 40, 45). For women over age 30, they assessed only screening (with HPV DNA testing up to three times per lifetime or VIA…
Cost-Effectiveness Analysis | Health/Medicine | Microsimulation | Calibration/Validation | Infectious Diseases | Chronic Disease/Risk | Clinical Care | Economics/Finance | Science/Technology | Sub-Saharan Africa